BSE filing, NSE: TEJNAKSH. Summary written from the filing by ALFA Finder's alert engine.
Tejnaksh Healthcare Ltd: key numbers
- Share price
- ₹12.83
- Market cap
- ₹26.06 Cr
- Revenue (annual)
- ₹10.79 Cr
- Net profit (annual)
- ₹1.23 Cr
- P/E (TTM)
- 21.1×Sector 54.5×
- Promoter holding
- 73.83%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tejnaksh Healthcare Ltd
All →Tejnaksh Healthcare Business Update
Tejnaksh Healthcare's Managing Director Dr. Ashish Rawandale-Patil was selected as a mentor for ES-TIP 2027. The honour is an international recognition of his medical innovation expertise.
Tejnaksh Healthcare Business Update
Tejnaksh Healthcare announced publication of a multicentric validation study of its Pflow device in the Indian Journal of Urology. The filing is a scientific publication update with no financial value.
Tejnaksh Healthcare Other Announcement
Tejnaksh Healthcare Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of SEBI LODR.
Tejnaksh Healthcare Management Change
Tejnaksh Healthcare shareholders approved the re-appointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second five-year term at the 18th Annual General Meeting.
Tejnaksh Healthcare Annual General Meeting
The company issued a notice for its Annual General Meeting scheduled for September 29, 2026, to consider financial statements, director appointments, and related party transaction approvals.
Tejnaksh Healthcare Annual Report
Tejnaksh Healthcare Limited has submitted its Annual Report for the financial year 2025-26. The filing includes audited standalone and consolidated financial statements along with governance reports.
Other debt & borrowing announcements
All →Brigade Enterprises Debt & Borrowing
Brigade Enterprises' subsidiary Venusta Ventures will issue rated NCDs to IFC under an investment framework agreement. No amount is disclosed in the filing.
Max Estates Debt & Borrowing: ₹350 Cr
Max Estates' board approved a ₹350 crore corporate guarantee for a wholly-owned subsidiary's term loan. Monitoring agency reports on its QIP and warrant proceeds were also filed.
- Value
- ₹350.0 Cr
Credent Connect N Care Debt & Borrowing: ₹4.5 Cr
Credent Connect N Care's board approved an unsecured inter-corporate loan of Rs 4.50 Crore to Kartavya Healtheon Private Limited. The loan carries 12% compounded interest after 25 November 2026 and gives the lender a right to up to 26% equity.
- Value
- ₹4.50 Cr
Amines & Plasticizers Debt & Borrowing
Amines & Plasticizers invited members to place unsecured deposits under Form DPT-1. Only resident members may subscribe, and the scheme is on the company website.
HEG Advanced Materials Debt & Borrowing: ₹50 Cr
HEG granted subsidiary Replus Engitech an unsecured revolving loan of Rs.50 Crore. It is repayable on demand at 9% interest, at arm's length.
- Value
- ₹50.00 Cr
- Execution
- Repayable on demand
Purple Finance Debt & Borrowing: ₹25 Cr
Purple Finance's finance committee approved issuing up to 25,000 senior secured NCDs aggregating ₹25 Crore on a private placement basis. The debentures carry an 11.50% coupon and a 30-month tenure.
- Value
- ₹25.00 Cr
- Execution
- 30 months from deemed date of allotment